ArticleAmerican journal of translational research2019
Artemether improves type 1 diabetic kidney disease by regulating mitochondrial function.
Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Protective Effect and Possible Mechanisms of Artemisinin and Its Derivatives for Diabetic Nephropathy: A Systematic Review and Meta-Analysis in Animal Models.Oxidative medicine and cellular longevity · 2022Pooled it
- Article
- Artemether Improves AβMolecular neurobiology · 2025Article
- Activation of sirtuin 3 and maintenance of mitochondrial homeostasis by artemisinin protect against diclofenac-induced kidney injury in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Artemisinin and Its Derivatives: Promising Therapeutic Agents for Age-Related Macular Degeneration.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Artemether Attenuates High Glucose-Induced Inflammation and Fibrogenesis in Renal Tubular Epithelial Cells by Modulating the TGF-Journal of diabetes research · 2025Article
- Artemether ameliorates type 1 diabetes mellitus by modulating glycolipid metabolism in skeletal muscle.American journal of translational research · 2025Article
- Artemether regulates liver glycogen and lipid utilization through mitochondrial pyruvate oxidation in db/db mice.American journal of translational research · 2024Article
- Artemether ameliorates adriamycin induced cardiac atrophy in mice.Molecular medicine reports · 2023Article
- Therapeutic potential of artemisinin and its derivatives in managing kidney diseases.Frontiers in pharmacology · 2023Review
- Combined treatment with niclosamide ethanolamine and artemether combination improves type 1 diabetes via the targeting of liver mitochondria.Experimental and therapeutic medicine · 2022Article
- Protective effect of natural products in the metabolic-associated kidney diseasesFrontiers in pharmacology · 2022Review
- Artemether attenuates renal tubular injury by regulating iron metabolism in mice with streptozotocin-induced diabetes.American journal of translational research · 2022Article
- Artemether Alleviates Diabetic Kidney Disease by Modulating Amino Acid Metabolism.BioMed research international · 2022Article
- Combination therapy with artemether and enalapril improves type 1 diabetic nephropathy through enhancing antioxidant defense.American journal of translational research · 2022Article
- Artemether attenuates renal tubular injury by targeting mitochondria in adriamycin nephropathy mice.American journal of translational research · 2022Article
- Artemether ameliorates kidney injury by restoring redox imbalance and improving mitochondrial function in Adriamycin nephropathy in mice.Scientific reports · 2021Article
- The Potential Roles of Artemisinin and Its Derivatives in the Treatment of Type 2 Diabetes Mellitus.Frontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many patients with type 1 diabetes mellitus suffer from progressive diabetic kidney disease (DKD). The progression of DKD is largely attributed to mitochondrial dysfunction, with key contributions from mitochondrial reactive oxygen species. Recent studies have revealed that the antimalarial drug artemether has antidiabetic effects. To identify potential effects on type 1 DKD in the present study, mice with streptozotocin-induced diabetes were treated with artemether. Treatment reduced urinary excretion of albumin and tubular injury biomarkers, increased serum albumin and total protein levels, and attenuated renal hypertrophy. In addition, artemether treatment prevented hyperglycemia, raised serum insulin levels, and restored glucagon/insulin and somatostatin/insulin ratios in islets. We found that artemether improved mitochondrial function and regulated redox balance in kidney. These results demonstrate that artemether provides renal protection in type 1 diabetes mellitus, which may be due to improved mitochondrial function.
Indexed as
Identifiers
31312396PMC6614617W2982258689What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.